Milliman
Life Sciences Firms Urged to Court ACOs as Value-Based Care Expands Across Medicaid, Medicare
Milliman argues life sciences companies should build strategies for engaging accountable care organizations (ACOs) given the growing share of Medicaid, Medicare, and commercial lives in value-based care arrangements, including a rising share of downside-risk contracts. While Medicaid VBC penetration (29.1% of lives, 21.1% in two-sided risk) is cited as supporting data, the piece's core audience and recommendations target pharma/life sciences strategy rather than Medicaid managed care operations directly.
This is outside commentary from Milliman, not part of Medicaid Monitor's independently scored news coverage.